Pharmaceutical

EC conditionally approves Regeneron’s Lynozyfic for multiple myeloma

The EC has granted conditional marketing approval to Regeneron Pharmaceuticals’ bispecific antibody Lynozyfic for treating multiple myeloma.

Apr 30, 2025 - 06:00
EC conditionally approves Regeneron’s Lynozyfic for multiple myeloma
The EC has granted conditional marketing approval to Regeneron Pharmaceuticals’ bispecific antibody Lynozyfic for treating multiple myeloma.
Read the original article

Tags:

Previous Article

Prilenia and Ferrer to commercialise pridopidine in Europe

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Health insurance stocks tumble after UnitedHealth says Medicare enrollees are getting more care

STAT+: Health insurance stocks tumble after UnitedHealt...

Jun 14, 2023

STAT+: Obesity drug Wegovy gets FDA approval to add cardiovascular benefits on its label

STAT+: Obesity drug Wegovy gets FDA approval to add car...

Mar 8, 2024

Race for a first-to-market therapy for NASH heats up

Race for a first-to-market therapy for NASH heats up

Mar 21, 2023